Halozyme Therapeutics (HALO) Shares Outstanding (2016 - 2025)
Historic Shares Outstanding for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $117.8 million.
- Halozyme Therapeutics' Shares Outstanding fell 434.96% to $117.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $117.8 million, marking a year-over-year decrease of 434.96%. This contributed to the annual value of $117.8 million for FY2025, which is 434.96% down from last year.
- Per Halozyme Therapeutics' latest filing, its Shares Outstanding stood at $117.8 million for Q4 2025, which was down 434.96% from $117.5 million recorded in Q3 2025.
- In the past 5 years, Halozyme Therapeutics' Shares Outstanding registered a high of $143.4 million during Q1 2021, and its lowest value of $117.5 million during Q3 2025.
- For the 5-year period, Halozyme Therapeutics' Shares Outstanding averaged around $130.6 million, with its median value being $131.8 million (2023).
- Its Shares Outstanding has fluctuated over the past 5 years, first soared by 592.18% in 2021, then tumbled by 759.54% in 2025.
- Over the past 5 years, Halozyme Therapeutics' Shares Outstanding (Quarter) stood at $137.5 million in 2021, then fell by 1.7% to $135.2 million in 2022, then fell by 6.2% to $126.8 million in 2023, then decreased by 2.87% to $123.1 million in 2024, then fell by 4.35% to $117.8 million in 2025.
- Its Shares Outstanding was $117.8 million in Q4 2025, compared to $117.5 million in Q3 2025 and $117.6 million in Q2 2025.